Compare Micron Technology, Inc. (MU) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Micron Technology, Inc. vs ResMed Inc. — how do they compare? Micron Technology, Inc. trades at $1,019.71 (market cap $1.13T), while ResMed Inc. trades at $219.5 (market cap $31.89B). The key difference: Micron Technology, Inc. is far larger — about 35.4× ResMed Inc.'s market cap, and ResMed Inc. pays the higher dividend (1.19%). Which is the better fit depends on your goals.
| MU | RMD | |
|---|---|---|
Market Cap | $1.13T | $31.89B |
Sector | Technology | Health |
52-Week High | $1.21K | $283.28 |
52-Week Low | $140.00 | $182.82 |
Enterprise Value | $1.11T | $31.24B |
Dividend Yield | 0.05% | 1.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Micron Technology (MU) trades at $1,000.26, down 1.61% today but remains in a strong uptrend, supported by bullish technical signals and robust fundamentals. The company reported Q1 2026 EPS of $25.11, beating estimates by 20%, with revenue surging to $37.38 billion in 2025. Operating cash flow hit $17.53 billion, while analyst consensus is strongly bullish with an 82.9% buy rating and a $1,550 price target.
Outlook is positive due to AI-driven memory demand, with 2026 revenue projected at $90.3 billion. Risks include memory market cyclicality and supply constraints, but Micron's margin expansion and institutional support suggest further upside for investors seeking growth in semiconductor equities.
ResMed (RMD) trades at $221.05, down 3.2% amid a bearish technical signal, though it holds above key support at $218. The company reported strong Q4 2026 results with EPS of $2.95 beating estimates, and revenue grew 9% to a record $1.5 billion. However, weaker fiscal 2027 revenue guidance has pressured the stock. Fundamentals remain solid with a 26.94% net income margin and robust cash flow from operations of $1.75 billion in 2025.
The outlook is mixed; strong profitability and consistent earnings beats support upside toward the $235.70 consensus price target, but near-term sentiment is cautious due to the soft sales forecast and ongoing legal investigations. Key risks include competitive pressures and execution on guidance. Institutional buying by firms like HSBC and Canada Pension Plan provides confidence in long-term value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Micron Technology, Inc.
Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
